… Moreover, apart from the current pharmacological interventions, hepatic resection … systematic
review included phase I, II, III, and IV clinical trials (CTs) and randomized controlled trials (…

… , and erlotinib (G + O + E) was evaluated in a phase II trial … HCC, but further study with
phase III clinical trials is needed. … of advanced HCC in a randomized, open-label, phase II/III …

… There were ten phase III studies, three phase II studies, and two phase II–III studies.
Additional details are shown in Table 1. There was no evidence of serious imbalance in the …

… advanced HCC in terms of epidemiology, genetics, clinical management, and outcomes in
clinical trials [11,… In a large, randomized phase II/III study, sintilimab plus IBI305 compared with …

… , and MKIs using data from 20 phase II-III RCTs. Our findings … that the combination of
Sorafenib+Erlotinib was the best in … are still being studied in clinical trials. However, accessibility …

… through unity for bevacizumab plus erlotinib, linifanib, and … majority of clinical trials in
first-line hepatocellular carcinoma … meta-analysis were to systematically review and compare …

… Phase II/III clinical trials of early- and intermediate-stage HCC … of sorafenib plus
erlotinib in patients with advanced hepatocellular carcinoma. J Clin Oncol. 2015;33(6):559–66. …

… atmosphere in the HCC drug research and development field. … review summarizes FDA-approved
agents for HCC, elucidates promising agents evaluated in clinical phase I/II/III trials …

… advanced hepatocellular carcinoma (HCC). We reviewed all the trials that tested these drugs.
Most … The objectives of this study were to identify all clinical trials that evaluated treatments …

… On the basis of these encouraging results, a phase III multicenter clinical trial (LEAP-002
TRIAL) is ongoing to assess efficacy and safety of lenvatinib plus pembrolizumab compared to …